The efficacy and cost of aprotinin in children undergoing reoperative open heart surgery

Celia C. D'Errico, Jay R. Shayevitz, Sarah J. Martindale, Ralph S. Mosca, Edward L. Bove

Research output: Contribution to journalArticle

65 Citations (Scopus)

Abstract

We performed a prospective, randomized, placebo-controlled, double- blind trial to assess the efficacy of aprotinin in 61 children (median age 3.7 yr) undergoing reoperative open heart surgery (OHS). Three demographically similar groups were studied: large-dose aprotinin (ALD), small-dose aprotinin (ASD), and placebo (P). Over the first 24 postoperative hours fewer patients in the aprotinin groups received packed red cells (ALD, 53%; ASD, 89%; and P, 95%; P = 0.001), platelets (ALD, 32%; ASD, 50%; and P, 65%; P = 0.04), and fresh frozen plasma (ALD, 16%; ASD, 17%; and P, 60%; P = 0.003) than placebo patients. Most importantly, aprotinin patients had fewer exposures to banked blood components (ALD, median 1 U; and ASD, median 2 U) than P (median 6 U; P = 0.001), with no difference in overall complication rate. Use of aprotinin was associated with a savings in the patient charges for blood components, operating room time, and duration of hospitalization. In conclusion, aprotinin decreased the number of units of banked blood components used during the first 24 postoperative hours in reoperative pediatric OHS. Aprotinin thus decreases the risks associated with exposure to banked blood components and reduces hospital charges.

Original languageEnglish (US)
Pages (from-to)1193-1199
Number of pages7
JournalAnesthesia and Analgesia
Volume83
Issue number6
StatePublished - 1996
Externally publishedYes

Fingerprint

Aprotinin
Thoracic Surgery
Costs and Cost Analysis
Placebos
Hospital Charges
Operating Rooms
Hospitalization
Blood Platelets

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this

D'Errico, C. C., Shayevitz, J. R., Martindale, S. J., Mosca, R. S., & Bove, E. L. (1996). The efficacy and cost of aprotinin in children undergoing reoperative open heart surgery. Anesthesia and Analgesia, 83(6), 1193-1199.

The efficacy and cost of aprotinin in children undergoing reoperative open heart surgery. / D'Errico, Celia C.; Shayevitz, Jay R.; Martindale, Sarah J.; Mosca, Ralph S.; Bove, Edward L.

In: Anesthesia and Analgesia, Vol. 83, No. 6, 1996, p. 1193-1199.

Research output: Contribution to journalArticle

D'Errico, CC, Shayevitz, JR, Martindale, SJ, Mosca, RS & Bove, EL 1996, 'The efficacy and cost of aprotinin in children undergoing reoperative open heart surgery', Anesthesia and Analgesia, vol. 83, no. 6, pp. 1193-1199.
D'Errico, Celia C. ; Shayevitz, Jay R. ; Martindale, Sarah J. ; Mosca, Ralph S. ; Bove, Edward L. / The efficacy and cost of aprotinin in children undergoing reoperative open heart surgery. In: Anesthesia and Analgesia. 1996 ; Vol. 83, No. 6. pp. 1193-1199.
@article{3943ae5f4e3b4f668fb251bf8a5f120e,
title = "The efficacy and cost of aprotinin in children undergoing reoperative open heart surgery",
abstract = "We performed a prospective, randomized, placebo-controlled, double- blind trial to assess the efficacy of aprotinin in 61 children (median age 3.7 yr) undergoing reoperative open heart surgery (OHS). Three demographically similar groups were studied: large-dose aprotinin (ALD), small-dose aprotinin (ASD), and placebo (P). Over the first 24 postoperative hours fewer patients in the aprotinin groups received packed red cells (ALD, 53{\%}; ASD, 89{\%}; and P, 95{\%}; P = 0.001), platelets (ALD, 32{\%}; ASD, 50{\%}; and P, 65{\%}; P = 0.04), and fresh frozen plasma (ALD, 16{\%}; ASD, 17{\%}; and P, 60{\%}; P = 0.003) than placebo patients. Most importantly, aprotinin patients had fewer exposures to banked blood components (ALD, median 1 U; and ASD, median 2 U) than P (median 6 U; P = 0.001), with no difference in overall complication rate. Use of aprotinin was associated with a savings in the patient charges for blood components, operating room time, and duration of hospitalization. In conclusion, aprotinin decreased the number of units of banked blood components used during the first 24 postoperative hours in reoperative pediatric OHS. Aprotinin thus decreases the risks associated with exposure to banked blood components and reduces hospital charges.",
author = "D'Errico, {Celia C.} and Shayevitz, {Jay R.} and Martindale, {Sarah J.} and Mosca, {Ralph S.} and Bove, {Edward L.}",
year = "1996",
language = "English (US)",
volume = "83",
pages = "1193--1199",
journal = "Anesthesia and Analgesia",
issn = "0003-2999",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - The efficacy and cost of aprotinin in children undergoing reoperative open heart surgery

AU - D'Errico, Celia C.

AU - Shayevitz, Jay R.

AU - Martindale, Sarah J.

AU - Mosca, Ralph S.

AU - Bove, Edward L.

PY - 1996

Y1 - 1996

N2 - We performed a prospective, randomized, placebo-controlled, double- blind trial to assess the efficacy of aprotinin in 61 children (median age 3.7 yr) undergoing reoperative open heart surgery (OHS). Three demographically similar groups were studied: large-dose aprotinin (ALD), small-dose aprotinin (ASD), and placebo (P). Over the first 24 postoperative hours fewer patients in the aprotinin groups received packed red cells (ALD, 53%; ASD, 89%; and P, 95%; P = 0.001), platelets (ALD, 32%; ASD, 50%; and P, 65%; P = 0.04), and fresh frozen plasma (ALD, 16%; ASD, 17%; and P, 60%; P = 0.003) than placebo patients. Most importantly, aprotinin patients had fewer exposures to banked blood components (ALD, median 1 U; and ASD, median 2 U) than P (median 6 U; P = 0.001), with no difference in overall complication rate. Use of aprotinin was associated with a savings in the patient charges for blood components, operating room time, and duration of hospitalization. In conclusion, aprotinin decreased the number of units of banked blood components used during the first 24 postoperative hours in reoperative pediatric OHS. Aprotinin thus decreases the risks associated with exposure to banked blood components and reduces hospital charges.

AB - We performed a prospective, randomized, placebo-controlled, double- blind trial to assess the efficacy of aprotinin in 61 children (median age 3.7 yr) undergoing reoperative open heart surgery (OHS). Three demographically similar groups were studied: large-dose aprotinin (ALD), small-dose aprotinin (ASD), and placebo (P). Over the first 24 postoperative hours fewer patients in the aprotinin groups received packed red cells (ALD, 53%; ASD, 89%; and P, 95%; P = 0.001), platelets (ALD, 32%; ASD, 50%; and P, 65%; P = 0.04), and fresh frozen plasma (ALD, 16%; ASD, 17%; and P, 60%; P = 0.003) than placebo patients. Most importantly, aprotinin patients had fewer exposures to banked blood components (ALD, median 1 U; and ASD, median 2 U) than P (median 6 U; P = 0.001), with no difference in overall complication rate. Use of aprotinin was associated with a savings in the patient charges for blood components, operating room time, and duration of hospitalization. In conclusion, aprotinin decreased the number of units of banked blood components used during the first 24 postoperative hours in reoperative pediatric OHS. Aprotinin thus decreases the risks associated with exposure to banked blood components and reduces hospital charges.

UR - http://www.scopus.com/inward/record.url?scp=0029958434&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029958434&partnerID=8YFLogxK

M3 - Article

VL - 83

SP - 1193

EP - 1199

JO - Anesthesia and Analgesia

JF - Anesthesia and Analgesia

SN - 0003-2999

IS - 6

ER -